James Edgemond Sells 21,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 21,000 shares of United Therapeutics stock in a transaction on Monday, December 1st. The shares were sold at an average price of $479.99, for a total transaction of $10,079,790.00. Following the sale, the chief financial officer directly owned 8,142 shares of the company’s stock, valued at $3,908,078.58. This trade represents a 72.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

James Edgemond also recently made the following trade(s):

• On Monday, November 24th, James Edgemond sold 21,000 shares of United Therapeutics stock. The stock was sold at an average price of $473.64, for a total transaction of $9,946,440.00.
• On Monday, November 17th, James Edgemond sold 21,000 shares of United Therapeutics stock. The stock was sold at an average price of $470.36, for a total value of $9,877,560.00.
• On Monday, November 10th, James Edgemond sold 21,000 shares of United Therapeutics stock. The shares were sold at an average price of $452.07, for a total value of $9,493,470.00.
• On Tuesday, November 4th, James Edgemond sold 21,000 shares of United Therapeutics stock. The stock was sold at an average price of $436.09, for a total value of $9,157,890.00.

United Therapeutics Price Performance

UTHR opened at $480.96 on Thursday. The company has a market capitalization of $20.71 billion, a PE ratio of 18.23, a price-to-earnings-growth ratio of 4.77 and a beta of 0.86. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $492.62. The business has a 50-day moving average of $450.60 and a 200-day moving average of $365.80.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping the consensus estimate of $6.89 by $0.27. The company had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.39 earnings per share. On average, equities research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Institutional Trading of United Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Darwin Global Management Ltd. acquired a new position in shares of United Therapeutics during the third quarter valued at about $317,617,000. Norges Bank acquired a new stake in United Therapeutics during the second quarter worth about $136,453,000. Invesco Ltd. increased its stake in United Therapeutics by 90.2% during the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after acquiring an additional 419,588 shares during the period. AQR Capital Management LLC raised its holdings in United Therapeutics by 40.1% in the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after acquiring an additional 364,713 shares in the last quarter. Finally, Nuveen LLC bought a new stake in shares of United Therapeutics in the 1st quarter worth approximately $83,533,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on UTHR shares. HC Wainwright increased their price target on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Bank of America raised their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research note on Tuesday, September 2nd. Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a report on Wednesday, October 29th. Royal Bank Of Canada upped their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. Finally, UBS Group raised their price target on United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $505.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.